Chronic pulmonary aspergillosis (CPA) is a disease that benefits from cavities as after-effects of 23 tuberculosis, presenting a high mortality rate. Serological tests like double agar gel 24 immunodiffusion test (DID) or the counterimmunoelectrophoresis (CIE) test have been routinely 25 used for CPA diagnosis in the absence of positive cultures; however, they have been replaced by 26 enzyme-linked immunoassay (ELISA), with a variety of methods. 27 This systematic review aims to compare the accuracy of the ELISA test with the reference test 28 (DID and/or CIE) in CPA diagnosis. It was conducted according to the Preferred Reporting Items 29 for Systematic Reviews and Meta-Analyzes (PRISMA). 30 The study was registered in PROSPERO under the registration number CRD42016046057. We 31 searched the electronic databases MEDLINE (PubMed), EMBASE (Elsevier), LILACS (VHL), 32 Cochrane library, and ISI Web of Science. Gray literature was researched in Google Scholars and 33 conference abstracts. We included articles with patients or serum samples from CPA patients who 34 underwent two serological tests: ELISA (index test) and IDD and/or CIE (reference test), using 35 the accuracy of the tests as a result. Original articles were considered without a restriction of date 36 or language. The pooled sensitivity, specificity, and summary receiver operating characteristic 37 curves were estimated. 38 We included 13 studies in the review, but only four studies were included in the meta-analysis. 39 The pooled sensitivities and specificities were 0.93 and 0.97 for the ELISA test. For the reference 40 test (DID and/or CIE), these values were 0.64 and 0.99. Analyses of summary receiver operating 41 characteristic curves yielded 0.99 for ELISA and 0.99 for the reference test (DID and/or CIE). Our 46 Chronic pulmonary aspergillosis (CPA) is a slow and progressive lung disease caused by 47 Aspergillus spp. that develops in preexisting cavities of patients with chronic respiratory diseases, 48 and pulmonary tuberculosis is its main predisposing factor, with a global prevalence estimated at 49 1.2 million cases [1].I Its prognosis is poor, with 38-85% mortality in five years [1,2].
Introduction
Two reviewers (CEVC, JV) independently extracted the following data from each included study:
136
-Study characteristics: author, year of publication, country, design, and sample size. Assessment of methodological quality 144 For this review, we used the QUADAS-2 tool to assess the methodological quality of 145 studies [18] . QUADAS-2 consists of four key domains: patient selection, index test, reference 146 standard, and flow and timing. We assessed all domains for the potential of risk of bias (ROB) and 147 the first three domains for concerns regarding applicability. Risk of bias is judged as "low", "high", 148 or "unclear". Two review authors independently completed QUADAS-2 and resolved 149 disagreements through discussion. 152 We used data reported in the true positive (TP), false positive (FP), true negative (TN) and 153 false negative (FN) format to calculate sensitivity and specificity estimates and 95% confidence 154 intervals (CIs) for individual studies. Summary positive (LR+) and negative (LR-) likelihood ratios 155 and summary diagnostic odds ratio (DOR) were obtained from the bivariate analysis. We used the clinical interpretation of likelihood ratios [19] as follows: conclusive evidence (LR+>10 and LR-157 <0.1), strong diagnostic evidence (LR+ >5 to 10 and LR-0.1 to <0.2), weak diagnostic evidence 158 (LR+ >2 to 5 and LR-0.2 to <0.5) and negligible evidence (LR+ 1 to 2 and LR-0.5 to 1).
Statistical analysis and data synthesis

159
In studies where it was possible to calculate sensitivity and specificity for the ELISA test 160 and DID and/or CIE, we calculated accuracy test and Youden's J statistic. The Youden's index 161 values range from zero to one inclusive, with the expectancy that the test will show a greater 162 proportion of positive results for the diseased group than for the control [20] .
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Studies were submitted to meta-analysis when three conditions were required: 1. sample 164 size greater than 20; 2. sensitivity and specificity were available for the index and the reference 165 tests; 3. healthy controls were included in the analysis. We presented individual studies and pooled 166 results graphically by plotting the estimates of sensitivity and specificity (and their 95% CIs), 172 We investigated heterogeneity by subgroup analyses. We addressed the main source of 173 heterogeneity: in-house and commercial ELISA tests. In-house tests have presented many 174 technical differences. We considered an I2 value close to 0% as having no heterogeneity between 175 studies, close to 25% with low heterogeneity, close to 50% with moderate heterogeneity and close 176 to 75% with high heterogeneity between studies [21].
Investigations of heterogeneity
Results
179
Study inclusion 180
A total of 2096 articles were identified in five databases, of which 2010 were searched 181 through a database and 63 articles were identified from other sources (manual search). After the 182 removal of duplicates, we remain with 1797 articles. After title / abstract exclusion, only 20 articles 183 were submitted to a full text read and 13 of them were included for the systematic review; only 184 four studies were included for the meta-analysis (see Fig 1) . Characteristics of the studies 191 The characteristics of the included studies are presented in S1Table. [22, 32, 33, 34] .
Fig1. Study flow diagram
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Nine articles presented DID as the reference test [22, 23, 25, 27, 28, 30, 32, 33, 34] ; an 197 article presented two reference tests, DID and CIE [34] and four studies presented only CIE as the 198 reference test [24, 26, 29, 31] .
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When we performed data extraction, some important differences were observed and 200 deserve to be highlighted. Seven articles performed in-house ELISA tests [22, 23, 28, 30, 32, 33, 201 34] and six articles described their studies with commercial tests [24, 25, 26, 27, 29, 31] . Different
202
Aspergillus antigens and cut-off points were used in the in-house ELISA tests; the articles that 203 used commercial tests also used several types of antigens and cutoff points included by authors 204 beyond those established by the manufacturer and are described in S1 Table. 205
In one article, we were unable to identify the number of patients evaluated with CPA, nor 206 was it possible to extract data from the 2×2 table for DID and ELISA [28]; in two articles it was 207 not possible to recover the DID data [25, 30] ; in another article, data were not obtained from CIE
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[31] and in another [32] , it was not possible to extract data for ELISA. In one study [33] , 20 sera from 13 patients were used and it was not possible to extract the accurate data per patient, besides Diagnostic accuracy 281 We present the We also constructed the sROC curves and calculated the area under ROC (AUROC) for 333 included studies ( Fig 6) . 
Investigations of heterogeneity
The limitations of this study rely in the primary studies. There were problems regarding 1. Page ID, Byanyima R, Hosmane S, Onyachi N, Opira C, Richardson M, Sawyer R,
